Literature DB >> 26139638

Acid Suppressive Therapy for Stress Ulcer Prophylaxis in Noncritically Ill Patients.

Minh T Hong1, Leslie C Monye1, Charles F Seifert2.   

Abstract

BACKGROUND: The current literature discourages the use of acid suppressive therapy (AST) for stress ulcer prophylaxis (SUP) in noncritically ill patients. However, several sources indicate that the majority of noncritically ill patients are given AST for SUP while there may only be a small proportion of high-risk patients who need SUP therapy. There is a new scoring system to aid practitioners in stratifying the risk of stress ulcer-related gastrointestinal bleeding in noncritically ill patients developed by Herzig et al and appropriately prescribe AST for SUP in this population.
OBJECTIVE: Our primary objective was to determine the current usage of AST in noncritically ill patients at a tertiary teaching hospital and use the new scoring system to identify non-intensive care unit patients who were inappropriately given AST.
METHODS: We retrospectively determined the percentage of noncritically ill patients who were given AST on medical floors between January 2010 and December 2012. After identifying these patients, we randomly selected a sample and retrospectively collected data from their medical record to determine the gastrointestinal bleeding risk score to determine if the patient was appropriately given AST.
RESULTS: Of the 42 600 admissions, 22 949 (53.7%) noncritically ill patients were given AST. A total of 442 patients were randomly selected for data collection and 156 patients were excluded. Gastrointestinal bleeding risk score was calculated in 286 patients. This new risk stratification tool identified 253 (88.5%) patients to have a low (≤7) and low-medium risk score (8-9).
CONCLUSIONS: A large percentage of noncritically ill patients were given AST during their hospital stay; 88.5% of these medications were given inappropriately to patients who were at extremely low risk of gastrointestinal bleeding. Using the above information and the AST prescribing patterns at our institution, we estimate a potential inpatient medication cost savings of $114 622 for the study period.
© The Author(s) 2015.

Entities:  

Keywords:  acid suppressive therapy; histamine type 2 antagonists; inpatients; proton pump inhibitors; stress ulcer prophylaxis

Mesh:

Substances:

Year:  2015        PMID: 26139638     DOI: 10.1177/1060028015592014

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  6 in total

1.  Appropriateness of Acid-suppressing Agents for Stress Ulcer Prophylaxis in Non-intensive Care Unit Setting in Saudi Arabia.

Authors:  Ala Malhis; Taghreed Alghamdi; Reem Alfandi; Zahra AlHaj Issa; Hadeel Alanazi; Hend Alfintoukh; Jaffer Bin Baqar; Sheraz Ali
Journal:  J Pharm Bioallied Sci       Date:  2019 Jan-Mar

2.  Sociedade Portuguesa de Cuidados Intensivos guidelines for stress ulcer prophylaxis in the intensive care unit.

Authors:  João João Mendes; Mário Jorge Silva; Luís Silva Miguel; Maria Albertina Gonçalves; Maria João Oliveira; Catarina da Luz Oliveira; João Gouveia
Journal:  Rev Bras Ter Intensiva       Date:  2019-02-28

3.  Proton pump inhibitors and 180-day mortality in the elderly after Clostridium difficile treatment.

Authors:  Evan Stuart Bradley; Emily Howe; Xun Wu; John P Haran
Journal:  Gut Pathog       Date:  2019-06-13       Impact factor: 4.181

4.  Current practice of stress ulcer prophylaxis in a surgical patient cohort in a German university hospital.

Authors:  Julia Rauch; Maciej Patrzyk; Claus-Dieter Heidecke; Tobias Schulze
Journal:  Langenbecks Arch Surg       Date:  2021-09-14       Impact factor: 3.445

5.  Involvement of microRNA/cystine/glutamate transporter in cold-stressed gastric mucosa injury.

Authors:  You-Cong Yin; Xiao-Hui Li; Xuan Rao; Yuan-Jian Li; Jie Du
Journal:  Front Pharmacol       Date:  2022-09-28       Impact factor: 5.988

Review 6.  Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppression.

Authors:  Carmelo Scarpignato; Luigi Gatta; Angelo Zullo; Corrado Blandizzi
Journal:  BMC Med       Date:  2016-11-09       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.